Tropisetron
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Tropisetron
|
|
| Systematic (IUPAC) name | |
| [(1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 1H-indole-3-carboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | A04 |
| PubChem | |
| Chemical data | |
| Formula | C17H20N2O2 |
| Mol. mass | 284.353 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ~60–80% |
| Protein binding | 71% |
| Metabolism | Hepatic (CYP3A4, CYP1A2, CYP2D6) |
| Half life | 6–8 hours |
| Excretion | Renal, Fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
X(AU) |
| Legal status | |
| Routes | Oral, IM |
Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia and New Zealand as Navoban, but is not available in the U.S.
[edit] Adverse effects
Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
[edit] External links
[edit] References
- ^ Muller, W.; T. Stratz (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scand J Rheumatic Suppl. 119: 44–48. PMID 15515413.
|
|||||||||||||||||||||||||||||
